IP Verse

Antineoplastic Combinations Of Neratinib And Capecitabine - EP3175853

The patent EP3175853 was granted to Wyeth on Nov 1, 2023. The application was originally filed on Aug 4, 2009 under application number EP16203986A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3175853

WYETH
Application Number
EP16203986A
Filing Date
Aug 4, 2009
Status
Granted And Under Opposition
Sep 29, 2023
Grant Date
Nov 1, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZJul 2, 2024ELKINGTON AND FIFEADMISSIBLE

Patent Citations (30) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2005059678
DESCRIPTIONUS2007104721
DESCRIPTIONUS4966891
DESCRIPTIONUS5453497
DESCRIPTIONUS5472949
DESCRIPTIONUS5476932
DESCRIPTIONUS6002008
DESCRIPTIONUS6288082
DESCRIPTIONUS6297258
DESCRIPTIONUS6780996
DESCRIPTIONUS7297795
DESCRIPTIONUS7399
DESCRIPTIONUS865
DESCRIPTIONWO9633978
DESCRIPTIONWO9633980
EXAMINATIONWO2010017163
OPPOSITIONWO2005018677
OPPOSITIONWO2006081985
OPPOSITIONWO2006113151
OPPOSITIONWO2006120557
OPPOSITIONWO2007056118
OPPOSITIONWO2008076143
OPPOSITIONWO2009042613
SEARCHWO2005018677
SEARCHWO2006081985
SEARCHWO2006113151
SEARCHWO2006120557
SEARCHWO2007056118
SEARCHWO2008076143
SEARCHWO2009042613

Non-Patent Literature (NPL) Citations (36) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- AL-MUHAMMED, J. MICROENCAPSUL., (1996), vol. 13, pages 293 - 306
DESCRIPTION- CHONN, CURR. OPIN. BIOTECHNOL., (1995), vol. 6, pages 698 - 708
DESCRIPTION- EYLES, J. PHARM. PHARMACOL., (1997), vol. 49, pages 669 - 674
DESCRIPTION- GAO, PHARM. RES., (1995), vol. 12, pages 857 - 863
DESCRIPTION- OSTRO, AM. J. HOSP. PHARM., (1989), vol. 46, pages 1576 - 1587
DESCRIPTION- PARKIN DM, FERNANDEZ LM, "Use of statistics to assess the global burden of breast cancer", BREAST JOURNAL., (200601), vol. 12, no. 1, pages 70 - 80
DESCRIPTION- PEGRAM MD ET AL., "The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer", CANCER TREATMENT & RESEARCH, (2000), vol. 103, pages 57 - 75
DESCRIPTION- RAMPAUL, RS ET AL., "Clinical value of epidermal growth factor receptor expression in primary breast cancer", ADV ANAT PATHOL, (2005), vol. 12, pages 271 - 273
DESCRIPTION- RAO, J. BIOMATER SCI. POLYM. ED, (1995), vol. 7, pages 623 - 645
DESCRIPTION- SMITH I., "Goals of treatment for patients with metastatic breast cancer", SEMINARS IN ONCOLOGY, (200602), vol. 33, no. 2, pages 2 - 5
DESCRIPTION- ZACZEK, A ET AL., "The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches", HISTOL HISTOPATHOL, (2005), vol. 20, pages 1005 - 1015, XP002752107
DESCRIPTION- XIA, W, "Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016", ONCOGENE, (2004), vol. 23, doi:doi:10.1038/sj.onc.1207166, pages 646 - 653, XP003000877
OPPOSITION- Anonymous, "Body surface area", Wikipedia, the free encyclopedia, (20170522), Wikipedia, the free encyclopedia, URL: https://en.wikipedia.org/w/index.php?title=Body_surface_area&oldid=781660289, XP093196065
OPPOSITION- Cardif R. D., D.W. Morris, L.J.T. Young And R. Strange, "Chapter 12. MuMTV GENOTYPE, PROTONEOPLASIA, AND TUMOR PROGRESSION", Proceedings of the International Breast Cancer Research Conference, Martinus Nijhoff Publishing, London, London, (19850301), XP093196069
OPPOSITION- Columbus Gina, "Neratinib Improves PFS in HER2+ Metastatic Breast Cancer", Onclive, (20181218), Onclive, URL: https://www.onclive.com/view/neratinib-improves-pfs-in-her2-metastatic-breast-cancer, XP093196063
OPPOSITION- Fda, "Prescribing information for TYKERB. TYKERB ® (lapatinib) tablets Initial U.S. Approval: 2007", HIGHLIGHTS OF PRESCRIBING INFORMATIO, (20070301), HIGHLIGHTS OF PRESCRIBING INFORMATIO, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022059lbl.pdf, XP093196067
OPPOSITION- Fleetwood Kelly, Ltd Quantics Consulting, Yellowlees Ann, Ltd Consulting, "What is indirect comparison?", Whatisseries, (20090101), Whatisseries, URL: https://www.quantics.co.uk/wp-content/uploads/2017/08/What-is-indirect-comparison.pdf, XP093196061
OPPOSITION- Jackisch, C., "Challenges in the treatment of ErbB2 (HER2)-positive breast cancer", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, GB , (20080301), vol. 6, no. 5, ISSN 1359-6349, pages 7 - 14, XP022559516
OPPOSITION- Wells James, Aulton M. E., "8. Pharmaceutical preformulation: the physicochemical properties of drug substance", Wells James, Aulton M. E., AULTON M.E. (ED.).2, PHARMACEUTICS. THE SCIENCE OF DOSAGE FORM DESIGN ED. 2, CHURCHILL LIVIGSTONE , (20020101), pages 113 - 138, 027702, ISBN 978-0-443-05517-1, XP093196068
OPPOSITION- Burstein H, Awada A, Badwe R, Dirix L, Tan A, Jacod S, Lustgarten S, Vermette J, Zacharchuk C., "6061 HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase 2 results in patients with advanced breast cancer.", Breast Cancer Research and Treatment, Springer US, New York, New York, (20071201), vol. 106, no. SUPPLEMENT 1, doi:10.1007/s10549-007-9793-3, ISSN 0167-6806, page S268, XP002591682
OPPOSITION- Reid, A. Vidal, L. Shaw, H. de Bono, J., "Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)", European Journal of Cancer, Elsevier, 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain, 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain, (20070201), vol. 43, no. 3, doi:10.1016/j.ejca.2006.11.007, ISSN 0959-8049, pages 481 - 489, XP005868776
OPPOSITION- Fry, D.W., "Inhibition of the Epidermal Growth Factor Receptor Family of Tyrosine Kinases as an Approach to Cancer Chemotherapy", Pharmacology & Therapeutics, ELSEVIER., GB, GB , (19990501), vol. 82, no. 2-3, doi:10.1016/S0163-7258(98)00050-3, ISSN 0163-7258, pages 207 - 218, XP027431733
OPPOSITION- GEYER C E ET AL., "Lapatinib plus capecitabine for HER2-positive advanced breast cancer", The New England journal of medicine, Massachusetts Medical Society, US, US , (20061228), vol. 355, doi:10.1056/NEJMoa064320, ISSN 0028-4793, pages 2733 - 2743, XP002498104
OPPOSITION- Mcneil Caroline, "Two Targets, One Drug for New EGFR Inhibitors", Journal of the National Cancer Institute, Oxford University Press, GB, GB , (20060816), vol. 98, no. 16, doi:10.1093/jnci/djj350, ISSN 0027-8874, pages 1102 - 1103, XP093196064
OPPOSITION- RABINDRAN S K, ET AL, "Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase", Cancer research, American Association for Cancer Research, San Diego, CA . Philadelphia (PA, San Diego, CA . Philadelphia (PA, (20040101), vol. 64, no. 11, doi:10.1158/0008-5472.CAN-03-2868, ISSN 0008-5472, pages 3958 - 3965, XP002318446
OPPOSITION- HEYMACH J V , NILSSON M, BLUMENSCHEIN G, "Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer", Clinical Cancer Research, Association for Cancer Research, US, US, (20060715), vol. 12, no. 14, doi:10.1158/1078-0432.CCR-06-0286, ISSN 1078-0432, pages 4441s - 4445s, XP002553862
OPPOSITION- OCANA A , PANDIELLA A, "Identifying breast cancer druggable oncogenic alterations: Lessons learned and future targeted options", Clinical Cancer Research, Association for Cancer Research, US, US, (20080215), vol. 14, no. 4, doi:10.1158/1078-0432.CCR-07-1630, ISSN 1078-0432, pages 961 - 970, XP002553863
OPPOSITION- Saura Cristina, Oliveira Mafalda, Feng Yin-Hsun, Dai Ming-Shen, Chen Shang-Wen, Hurvitz Sara A, Kim Sung-Bae, Moy Beverly, Delaloge Suzette, Gradishar William, Masuda Norikazu, Palacova Marketa, Trudeau Maureen E, Mattson Johanna, Yap Yoon Sim, Hou Ming-Feng, De Laurentiis Michelino, Yeh Yu-Min, Chang Hong-Tai, Yau Thomas, Wildiers Hans, Haley Barbara, Fagnani Daniele, Lu Yen-Shen, Crown John, Lin Johnson, Takahashi Masato, Takano Toshimi, Yamaguchi Miki, Fujii Takaaki, Yao Bin, Bebchuk Judith, Keyvanjah Kiana, Bryce Richard, Brufsky Adam, "Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial", Journal of Clinical Oncology, Grune & Stratton, (20190717), vol. 38, no. 27, doi:10.1200/JCO.20.00147, ISSN 0732-183X, pages 3138 - 3149, XP093196066
OPPOSITION- BOYD B , BOZZO J, CASTANER J, "Lapatanib: Oncolytic dual EGFR and erbB-2 inhibitor", Drugs of the Future, Prous Science, ES, ES , (20051201), vol. 30, no. 12, doi:10.1358/dof.2005.030.12.946811, ISSN 0377-8282, pages 1225 - 1239, XP002553861
OPPOSITION- LORUSSO P M , EDER J P, "Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology", Expert Opinion on Investigational Drugs, Informa Healthcare, UK, UK , (20080701), vol. 17, no. 7, doi:10.1517/13543784.17.7.1013, ISSN 1354-3784, pages 1013 - 1028, XP002553860
SEARCH- JACKISCH ET AL, "Challenges in the treatment of ErbB2 (HER2)-positive breast cancer", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, (20080301), vol. 6, no. 5, ISSN 1359-6349, pages 7 - 14, XP022559516 [I] 1-13 * page 9, column R, paragraphs 3,4 *
SEARCH- RABINDRAN S K ET AL, "Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, (20040101), vol. 64, no. 11, ISSN 0008-5472, pages 3958 - 3965, XP002318446 [A] 1,12-13 * pages 3963-4 *
SEARCH- HEYMACH J V ET AL, "Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer", CLINICAL CANCER RESEARCH 20060715 US, (20060715), vol. 12, no. 14, ISSN 1078-0432, pages 4441s - 4445s, XP002553862 [A] 1 * pages 4442-3 *
SEARCH- OCANA A ET AL, "Identifying breast cancer druggable oncogenic alterations: Lessons learned and future targeted options", CLINICAL CANCER RESEARCH 20080215 US, (20080215), vol. 14, no. 4, ISSN 1078-0432, pages 961 - 970, XP002553863 [A] 1 * table 1 *
SEARCH- BOYD B ET AL, "Lapatanib: Oncolytic dual EGFR and erbB-2 inhibitor", DRUGS OF THE FUTURE 200512 ES, (200512), vol. 30, no. 12, ISSN 0377-8282, pages 1225 - 1239, XP002553861 [A] 1-13 * pages 1233-4; table IV *
SEARCH- LORUSSO P M ET AL, "Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology", EXPERT OPINION ON INVESTIGATIONAL DRUGS 200807 GB, (200807), vol. 17, no. 7, ISSN 1354-3784, pages 1013 - 1028, XP002553860 [A] 1-13 * page 1018, column R, paragraph 2 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents